SeaStar Medical (ICU) Q4 2025 earnings review
Record Revenue as Pivotal Adult Trial Crosses 50% Mark
SeaStar Medical closed 2025 with an accelerating $420K in Q4 revenue, breaking its Q3 slump, though $105K of this was a research sale rather than commercial product adoption. The company successfully expanded its pediatric QUELIMMUNE customer base to 16 hospitals over the year. However, the core valuation driver remains the pivotal NEUTRALIZE-AKI adult trial, which reached 181 enrollees and remains on track for late-2026 completion. With $12.0M in cash, drastically reduced operating expenses, and guidance of just ~$2M in 2026 revenue, SeaStar appears to have sufficient runway to reach its critical data readouts, provided cash burn remains tightly controlled.
🐂 Bull Case
Through equity offerings and debt reduction, SeaStar ended 2025 with $12.0M in cash (up from $1.8M at the end of 2024), providing critical runway to fund the expanded Phase 3 trial.
The NEUTRALIZE-AKI trial added 35 patients in Q4 to reach 181 total enrollees. The company is actively maintaining its target completion timeline of late 2026.
🐻 Bear Case
Excluding the $105K research grant sale, Q4 commercial product revenue was $315K. This is an improvement from Q3 ($183K) but still below Q2's peak ($338K), highlighting the slow hospital adoption cycle.
The Q3 decision to expand the pivotal trial from 200 to 339 patients implies that the treatment effect observed at the interim analysis was smaller than initially assumed, increasing the risk of missing the primary endpoint.
⚖️ Verdict: ⚪
Neutral. The company successfully stabilized its balance sheet and is executing on clinical enrollment. However, commercial revenues remain immaterial, and the ultimate success of the company rests entirely on the binary outcome of the expanded adult AKI trial in late 2026.
Key Themes
Pivotal Trial Enrollment Stays on Track
The NEUTRALIZE-AKI adult trial is the primary value driver, addressing a market approximately 50 times larger than the pediatric indication. SeaStar successfully enrolled 35 patients in Q4, bringing the total to 181 (over 50% of the 339 target). Management confirmed that the trial is on pace to complete enrollment around the end of 2026, opening the door for a modular Premarket Application (PMA) submission.
Hospital Base Expansion
SeaStar added 13 new top-rated children's hospitals during 2025, bringing the total commercial customer base for QUELIMMUNE to 16. This expanding footprint lays the groundwork for recurring revenue, assuming the company can convert initial trial orders into standard-of-care protocols.
Lumpy Revenue Trajectory
Despite growing the hospital network, commercial adoption remains unpredictable. Pure product revenue in Q4 ($315K) was lower than the $338K achieved two quarters ago. The mandatory FDA post-approval registry requirement continues to force hospitals into lengthy 6-8 month Institutional Review Board (IRB) cycles, acting as a severe bottleneck to rapid sales acceleration.
Flawless Gross Margins Achieved
Cost of goods sold for Q4 was just $12,000 against $420,000 in revenue, validating management's claim of sustainable >90% gross margins. As sales volume scales, this margin profile will allow revenue to drop directly to the bottom line, substantially aiding the cash burn profile.
Platform Innovation: Cardiorenal Syndrome (CRS)
Management continues to position the Selective Cytopheretic Device (SCD) as a platform technology for hyperinflammation. SeaStar advanced its pipeline by initiating the NEUTRALIZE-CRS clinical trial, targeting 20 ICU patients with chronic heart failure who are ineligible for LVAD implants. Success here could validate the therapy's use beyond Acute Kidney Injury (AKI).
Other KPIs
Stable. The company demonstrated excellent financial discipline. Total operating expenses declined 26% YoY from $18.0M in 2024. This included a drop in R&D (from $9.1M to $7.5M) and G&A (from $8.9M to $5.8M) despite running a larger clinical trial, driven by reduced personnel, consulting, and legal costs.
Massive improvement from $1.8M at the end of 2024. Through various equity offerings totaling approximately $23.9M in capital raised during 2025, SeaStar has successfully fortified its balance sheet. With quarterly cash burn averaging roughly $3.0M - $3.5M, this runway is sufficient to last well into 2026, though a future raise may be required before trial completion.
Guidance
Accelerating. This implies roughly 75% growth compared to the $1.13M in pure commercial product sales generated in 2025 (excluding the $105K research sale). This confirms management expects adoption to be steady but still relatively small in absolute terms until adult indication approval.
Accelerating. Management plans to double the active customer base from the 16 hospitals established by the end of 2025, pushing the total to over 30.
Stable. The company maintained its timeline guidance from Q3, signaling confidence that the activation of additional clinical trial sites is successfully offsetting the burden of the expanded 339-patient enrollment target.
Key Questions
FDA Registry Exemption Status
In previous quarters, management mentioned approaching the FDA with real-world survival data to request relief from the mandatory pediatric registry. What is the status of those discussions, and could exemption happen in 2026?
Hospital Reorder Rates
Of the 16 pediatric hospitals currently active, what percentage have placed their second or third commercial order? How is the depth of penetration trending versus initial stocking?
Cash Runway and Funding the Expanded Trial
With the adult AKI trial expanding from 200 to 339 patients and pushing completion to late 2026, does the current $12.0M cash balance fund operations through the data readout, or should investors anticipate an additional capital raise in H2 2026?